Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

NCT05981235 PHASE1 COMPLETED

This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18.2+ GI tumors.

Details

Lead sponsor	Peking University
Phase	PHASE1
Status	COMPLETED
Enrolment	8
Start date	Thu Dec 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Gastrointestinal Tumors

Interventions

• AZD6422 CLDN18.2 CAR-T product

Countries

China